These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713 [TBL] [Abstract][Full Text] [Related]
4. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells. Jacob D; Schumacher G; Bahra M; Davis J; Zhu HB; Zhang LD; Teraishi F; Neuhaus P; Fang BL World J Gastroenterol; 2005 May; 11(17):2552-6. PubMed ID: 15849810 [TBL] [Abstract][Full Text] [Related]
5. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter]. Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959 [TBL] [Abstract][Full Text] [Related]
6. Cancer gene therapy using a novel secretable trimeric TRAIL. Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699 [TBL] [Abstract][Full Text] [Related]
7. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304 [TBL] [Abstract][Full Text] [Related]
8. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter. Jacob D; Bahra M; Schumacher G; Neuhaus P; Fang B Anticancer Res; 2004; 24(5A):3075-9. PubMed ID: 15517918 [TBL] [Abstract][Full Text] [Related]
9. [Killing effect of Ad.TERT-TRAIL on tumor cell lines and its mechanism]. Tang YX; Chen Y; Gu JF; Qi R; Zou WG; Jiang LL; Liu XY Ai Zheng; 2005 May; 24(5):536-42. PubMed ID: 15890093 [TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated gene transfer of caspase-8 sensitizes human adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand. Yasui H; Adachi M; Hamada H; Imai K Int J Oncol; 2005 Feb; 26(2):537-44. PubMed ID: 15645141 [TBL] [Abstract][Full Text] [Related]
11. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Katz MH; Spivack DE; Takimoto S; Fang B; Burton DW; Moossa AR; Hoffman RM; Bouvet M Ann Surg Oncol; 2003 Aug; 10(7):762-72. PubMed ID: 12900367 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289 [TBL] [Abstract][Full Text] [Related]
15. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Kim K; Takimoto R; Dicker DT; Chen Y; Gazitt Y; El-Deiry WS Int J Oncol; 2001 Feb; 18(2):241-7. PubMed ID: 11172588 [TBL] [Abstract][Full Text] [Related]
16. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894 [TBL] [Abstract][Full Text] [Related]
18. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678 [TBL] [Abstract][Full Text] [Related]